Literature DB >> 27318168

Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management.

Zdenek Kleibl1, Vessela N Kristensen2.   

Abstract

The presence of breast cancer in any first-degree female relative in general nearly doubles the risk for a proband and the risk gradually increases with the number of affected relatives. Current advances in molecular oncology and oncogenetics may enable the identification of high-risk individuals with breast-cancer predisposition. The best-known forms of hereditary breast cancer (HBC) are caused by mutations in the high-penetrance genes BRCA1 and BRCA2. Other genes, including PTEN, TP53, STK11/LKB1, CDH1, PALB2, CHEK2, ATM, MRE11, RAD50, NBS1, BRIP1, FANCA, FANCC, FANCM, RAD51, RAD51B, RAD51C, RAD51D, and XRCC2 have been described as high- or moderate-penetrance breast cancer-susceptibility genes. The majority of breast cancer-susceptibility genes code for tumor suppressor proteins that are involved in critical processes of DNA repair pathways. This is of particular importance for those women who, due to their increased risk of breast cancer, may be subjected to more frequent screening but due to their repair deficiency might be at the risk of developing radiation-induced malignancies. It has been proven that cancers arising from the most frequent BRCA1 gene mutation carriers differ significantly from the sporadic disease of age-matched controls in their histopathological appearances and molecular characteristics. The increased depth of mutation detection brought by next-generation sequencing and a better understanding of the mechanisms through which these mutations cause the disease will bring novel insights in terms of oncological prevention, diagnostics, and therapeutic options for HBC patients.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Breast cancer risk; Hereditary breast cancer

Mesh:

Substances:

Year:  2016        PMID: 27318168     DOI: 10.1016/j.breast.2016.05.006

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  33 in total

1.  Nano-Co-Delivery of Berberine and Anticancer Drug Using PLGA Nanoparticles: Exploration of Better Anticancer Activity and In Vivo Kinetics.

Authors:  Iliyas Khan; Gaurav Joshi; Kartik T Nakhate; Raj Kumar; Umesh Gupta
Journal:  Pharm Res       Date:  2019-08-16       Impact factor: 4.200

2.  Group Selection May Explain Cancer Predisposition and Other Human Traits' Evolution.

Authors:  Konstantinos Voskarides
Journal:  J Mol Evol       Date:  2018-04-05       Impact factor: 2.395

3.  Recommendations on screening for breast cancer in women aged 40-74 years who are not at increased risk for breast cancer.

Authors:  Scott Klarenbach; Nicki Sims-Jones; Gabriela Lewin; Harminder Singh; Guylène Thériault; Marcello Tonelli; Marion Doull; Susan Courage; Alejandra Jaramillo Garcia; Brett D Thombs
Journal:  CMAJ       Date:  2018-12-10       Impact factor: 8.262

4.  First Two Cases of Bloom Syndrome in Russia: Lack of Skin Manifestations in a BLM c.1642C>T (p.Q548X) Homozygote as a Likely Cause of Underdiagnosis.

Authors:  Evgeny N Suspitsin; Farida I Sibgatullina; Lydia V Lyazina; Evgeny N Imyanitov
Journal:  Mol Syndromol       Date:  2017-01-17

Review 5.  Breast cancer in adolescents and young adults.

Authors:  Rebecca H Johnson; Carey K Anders; Jennifer K Litton; Kathryn J Ruddy; Archie Bleyer
Journal:  Pediatr Blood Cancer       Date:  2018-08-28       Impact factor: 3.167

Review 6.  Glycosylation and its implications in breast cancer.

Authors:  Danielle A Scott; Richard R Drake
Journal:  Expert Rev Proteomics       Date:  2019-07-25       Impact factor: 3.940

Review 7.  Dormant origins as a built-in safeguard in eukaryotic DNA replication against genome instability and disease development.

Authors:  Naoko Shima; Kayla D Pederson
Journal:  DNA Repair (Amst)       Date:  2017-06-09

Review 8.  Risk-Reducing Options for Women with a Hereditary Breast Cancer Predisposition.

Authors:  Ismail Jatoi
Journal:  Eur J Breast Health       Date:  2018-10-01

9.  Overexpressed XRCC2 as an independent risk factor for poor prognosis in glioma patients.

Authors:  Zhendong Liu; Wang Zhang; Xingbo Cheng; Hongbo Wang; Lu Bian; Jialin Wang; Zhibin Han; Yanbiao Wang; Xiaoyu Lian; Binfeng Liu; Zhishuai Ren; Bo Zhang; Zhenfeng Jiang; Zhiguo Lin; Yanzheng Gao
Journal:  Mol Med       Date:  2021-05-29       Impact factor: 6.354

10.  Male and female breast cancer: the two faces of the same genetic susceptibility coin.

Authors:  Susana Nunes Silva; Bruno Costa Gomes; Saudade André; Ana Félix; António Sebastião Rodrigues; José Rueff
Journal:  Breast Cancer Res Treat       Date:  2021-05-03       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.